Do Analysts Expect ADC Therapeutics SA (ADCT) Stock to Rise After It Has Gained 47.76% in a Month?

Analysts who follow ADC Therapeutics SA (ADCT) on average expect it to gain 601.01% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns ADCT an Analyst Ranking of 33, which means it ranks higher than 33 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating ADCT a Buy today. Find out what this means to you and get the rest of the rankings on ADCT!

See Full ADCT Report

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With ADC Therapeutics SA Stock Today?

ADC Therapeutics SA (ADCT) stock is trading at $0.99 as of 12:37 PM on Friday, Dec 1, an increase of $0.16, or 18.89% from the previous closing price of $0.83. The stock has traded between $0.86 and $0.99 so far today. Volume today is 380,090 compared to average volume of 363,493. Click Here to get the full Stock Report for ADC Therapeutics SA stock.